Optimizing outcomes in pregnant women with epilepsy

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 10, 2005, Pages 938-945

  Jeha, Lara E ^a   Morris, Harold H ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIAZEPAM; ESTROGEN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOLIC ACID; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROGESTERONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; VITAMIN K GROUP;

ARTICLE; BLEEDING DISORDER; BREAST FEEDING; CONGENITAL MALFORMATION; CONTRACEPTION; DISEASE CONTROL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; EPILEPSY; FETUS DISEASE; FETUS MALFORMATION; FOLLOW UP; HEALTH CARE PLANNING; HUMAN; MATERNAL CARE; MEDICAL RESEARCH; NEURAL TUBE DEFECT; NEWBORN DISEASE; OBSTETRIC CARE; PREGNANCY; PREGNANCY COMPLICATION; PUERPERIUM; RISK ASSESSMENT; RISK MANAGEMENT; SCREENING TEST; SEIZURE; TERATOGENICITY; VITAMIN SUPPLEMENTATION; WITHDRAWAL SYNDROME;

EID: 27744594961     PISSN: 08911150     EISSN: 08911150     Source Type: Journal    
DOI: 10.3949/ccjm.72.10.938     Document Type: Article

References (39)

1. Yerby MS. Quality of life, epilepsy advances, and the evolving role of anticonvulsants in women with epilepsy. Neurology 2000; 55(suppl 1):S21-S31.
2. Vajda FJ, O'Brien TJ, Hitchcock A, Graham J, Lander C. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci 2003; 10:543-549.
3. Pennell PB. Pregnancy in the woman with epilepsy: maternal and fetal outcomes. Semin Neurol 2002; 22:299-308.
4. Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA 1986; 256:238-240.
5. Practice parameter: management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1998; 51:944-948.
6. Stumpf DA, Frost M. Seizures, anticonvulsants, and pregnancy. Am J Dis Child 1978; 132:746-748.
7. Zahn CA, Morrell MJ, Collins SD, Labiner DM, Yerby MS. Management issues for women with epilepsy: a review of the literature. Neurology 1998; 51:949-956.
8. Berg AT, Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology 1994; 44:601-608.
9. Guberman A. Hormonal contraception and epilepsy. Neurology 1999; 53(suppl 1):S38-540.
10. Yerby MS. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology 2003; 61(suppl 2):S23-S26.
11. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608-1614.
12. Rothenberg SP, da Costa MP, Sequeira JM, et al. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 2004; 350:134-142.
13. Roos KL, et al. Neurologic disorders and pregnancy. In: Mancall EL, Munset TH, editors. Continuum: Lifelong Learning in Neurology 2000. Philadelphia: Lippincott Williams & Wilkins, 2000 (vol 6; number 1): 8-63.
14. Schmidt D. The effect of pregnancy on the natural history of epilepsy: review of literature. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D, eds. Epilepsy, Pregnancy, and the Child. New York: Raven Press; 1982:3-14.
15. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 1994; 35:122-130.
16. Bardy AH. Seizure frequency in epileptic women during pregnancy and puerperium, results of the prospective Helsinki study. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D, eds. Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:27-31.
17. Klein P, Herzog AG. Hormonal effects on epilepsy in women. Epilepsia 1998; 39(suppl 8):S9-S16.
18. Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology 1992; 42(suppl 5):12-16.
19. Tran TA, Leppik IE, Blesi K, Sathanandan ST, Remmel R. Lamotrigine clearance during pregnancy. Neurology 2002; 59:251-255.
20. Finnell RH, Nau H, Yerby MS. General principles: teratogenicity of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic Drugs. 4th ed. New York: Raven Press, 1995:209-230.
21. Yerby MS, Leavitt A, Erickson DM, et al. Antiepileptics and the development of congenital anomalies. Neurology 1992; 42(suppl 5):132-140.
22. Samren EB, Van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38:981-990.
23. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344:1132-1138.
24. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004; 93:174-176.
25. Lamotrigine pregnancy registry: Interim Report. 1 September 1992 through 31 March 2004. Issued July 2004. Available at http://pregnancyregistry.gsk.com/lamotrigene.html. Last accessed August 25; 2005.
26. Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004; 45:1171-1175.
27. Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1986; 1:1392-1393.
28. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004; 61:673-678.
29. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003; 60:575-579.
30. Holmes LB, Lieberman ES, for the Scientific Advisory Committee of the AED (antiepileptic drug) Pregnancy Registry, Genetics and Teratology Unit, Pediatric Service, Massachusetts General Hospital, Boston, Massachusetts. Report of first positive findings from hospital-based AED Pregnancy Registry [abstract]. Teratology 2001; 63:250.
31. Alsdorf R, Wyszynski D, Holmes L, Nambisan M. Evidence of increased birth defects in the off-spring of women exposed to valproate during pregnancy: findings from the AED pregnancy registry, [abstract]. Birth Defects Res A Clin Mol Teratol 2004; 70:245.
32. Tennis P, Eldridge RR; International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 2002; 43:1161-1167.
33. Lindhout D, Meinardi H, Meijer J, Nau H. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992; 42(suppl 5):94-110.
34. Becerra JE, Khoury MJ, Cordero JF, Erickson JD. Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study. Pediatrics 1990; 85:1-9.
35. Werler MM, Louik C, Shapiro S, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. JAMA 1996; 275:1089-1092.
36. Pschirrer E, Monga M. Seizure disorders in pregnancy. Obstet Gynecol Clin North Am 2001; 28:601-611; vii.
37. Malone F, D'Alton M. Drugs in pregnancy: anticonvulsants. Semin Perinatol 1997; 21:114-123.
38. Ito S, Moretti M, Liau M, Koren G. Initiation and duration of breast-feeding in women receiving antiepileptics. Am J Obstet Gynecol 1995; 172:881-886.
39. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003; 61(suppl 2):S35-S42.